Associate Professor @UZH_en @Unispital_USZ @CCCZ_USZ studying the pathogenesis of cancer with a particular focus on TP53-mutant myeloid (pre-)malignancies
🔥New paper from our lab @UZH_en@Unispital_USZ@CCCZ_USZ 🔥
#ERCC6L2 disease is a relatively recently described inherited bone marrow failure syndrome. It is strongly associated with somatic #TP53mutations and #AML or #MDS development. 1/7
https://t.co/RCjzmBnb0Z
Excited to share our latest work. Applying advanced single-molecule and single-cell DNA sequencing methods, we uncover an extraordinary landscape of somatic mutations in immune checkpoint genes in autoimmune lymphocytes. [1/n] https://t.co/8kQZ0NWl7X
Ercc6l2 deficiency leads to replication stress, p53 pathway activation, and decreased Runx1 and Gata1 expression resulting in BMF. Read the plenary paper in Blood: https://t.co/tjdpXh2Nfk #plenarypaper#bloodjournal#p53
🔥New paper from our lab @UZH_en@Unispital_USZ@CCCZ_USZ 🔥
#ERCC6L2 disease is a relatively recently described inherited bone marrow failure syndrome. It is strongly associated with somatic #TP53mutations and #AML or #MDS development. 1/7
https://t.co/RCjzmBnb0Z
1/🔥 New paper from our lab!
#TP53-mutant clonal hematopoiesis (#CH) greatly increases risk for therapy-related #AML/MDS - but why?
We set out to dissect how mono- vs. biallelic #TP53 mutations drive leukemic evolution. https://t.co/bE4aSD61AG
@SanjayPatelMD Thank you so much for putting these findings in context! I have the impression that even when formal AEL criteria aren’t met, TP53-mutant myeloid neoplasms often show erythroid-dominant marrow findings. IMHO an under-appreciated pattern.
8/🍾🎉 Congratulations to #JonasFullin and the entire team, and many thanks to all collaborators!
📄 Read the full paper here:
“The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis” https://t.co/bE4aSD61AG